ImmunityBio’s (IBRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note published on Monday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd.

ImmunityBio Trading Down 6.2 %

Shares of IBRX stock opened at $2.56 on Monday. ImmunityBio has a twelve month low of $2.50 and a twelve month high of $10.53. The stock has a fifty day simple moving average of $4.07 and a two-hundred day simple moving average of $4.41. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -2.78 and a beta of 0.86.

Institutional Trading of ImmunityBio

A number of hedge funds have recently bought and sold shares of the stock. State Street Corp raised its position in shares of ImmunityBio by 10.1% in the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after acquiring an additional 790,408 shares in the last quarter. Barclays PLC raised its holdings in ImmunityBio by 127.4% in the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after purchasing an additional 202,248 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of ImmunityBio during the third quarter valued at about $136,000. Bank of New York Mellon Corp lifted its position in shares of ImmunityBio by 37.9% during the second quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock valued at $3,928,000 after buying an additional 170,742 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after buying an additional 4,545 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.